James Whyte > 8 New Square Intellectual Property > London, England > Lawyer Profile
8 New Square Intellectual Property Offices
8 New Square
- Go to...
Barrister specialising in intellectual property law, with a particular emphasis on technically complex patent cases in biotechnology, pharmaceuticals, telecoms and electronics. Scheduled trials include GSK v Fibrogen (iron deficiency drugs), ABI v Heineken (blow moulded containers), Pfizer v Wyeth (vaccine formulation). Recent cases include Illumina v Ariosa (cell-free foetal DNA enrichment), Silence v Alnylam (RNAi; settled shortly before trial), Pacific Biosciences v Oxford Nanopore (DNA sequencing; settled shortly before trial), Chugai v UCB Pharma (US antibody engineering patent), Illumina v Premaitha (prenatal diagnosis), Astex v AstraZeneca (drug development contractual dispute), Varian v Elekta (MRI/radiotherapy), Regeneron v Kymab (antibody engineering), EMGS v PGS (electromagnetic hydrocarbon prospecting), Wobben v Siemens (wind turbines), Vestergaard Frandsen v Bestnet (insecticidal mosquito nets), Novartis v Hospira (injunction pending appeal), Medimmune v Novartis (phage display), Siemens v Seagate (magnetoresistance, N.Ireland).
Called 2005, Lincoln’s Inn.
Chancery Bar Association, IP Bar Association.
BA in Natural Sciences (1st), Cambridge; PhD in molecular cell biology, Cambridge; postgraduate diploma in law (distinction), City University; bar vocational course (outstanding), BPP.